Latest News Stories

Pression, Inc., a medical technology innovator specializing in non-invasive circulatory health, announced today that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for...

The landscape of External Counterpulsation (ECP) underwent a significant transformation in 2025, evolving from a "last-resort" treatment for refractory angina into a front-line therapy for microvascular disease, cognitive...

Following the successful conclusion of our WaveCREST Clinical Study, we are very proud to announce the submission of our 510K to FDA. This tremendous milestone was made possible...